DRG Epidemiology’s coverage of chronic daily headache (CDH) presents epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the…
Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
Approved therapies for Alzheimer's disease (AD) comprise symptomatic agents (e.g., donepezil, memantine) that provide only modest cognitive benefit for a limited period of time. A rapidly…
DRG Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (…
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas),…
Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF,…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related death in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…